🇺🇸 SECGalmed Pharmaceuticals Ltd.Qwen · 实盘不做把握 2/10不做原因:无增量信息
北京时间·🕒 发布 18:08:34·⟳ 抓取 18:09:04 +30s·⚡ 决策 09-08 20:07:49 +1h58m·49.1 天前
Galmed Pharmaceuticals 收到纳斯达克通知，已重新满足 1 美元最低买价要求（Rule 5550(a)(2)），退市风险事项结案，公司 9 月 8 日提交 6-K 备案
这是一份例行的纳斯达克上市合规结案备案：达标事实由 8/20–9/2 的市场价格自身构成，9/3 已由交易所通知、9/8 才见诸 6-K，属于滞后确认而非新信息；文件明确不含业绩、临床、融资或证券发行条款变化。同时标的为总市值约 404 万美元、日均成交额约 44 万美元、盘前成交 22 股的极端微型股，且近 20 日 -19.4%、13 周轨迹自 118 回落至 92 处于下行形状。既无增量事实、也无正期望与可执行结构，故 AVOID。
📄 原文Galmed Pharmaceuticals Ltd.↗ 原文
----- form6-k.htm ----- 6-K 1 form6-k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 F…
不做 Galmed Pharmaceuticals Ltd.（GLMD.US）
例行行政备案，无增量事实：纳斯达克重新满足最低买价的达标条件就是 8/20–9/2 连续 10 日收盘≥1 美元，市场早已完整观测并在价格中体现，9/8 的 6-K 只是滞后确认，且文件未披露任何业绩、临床、融资或证券发行条款变化。叠加结构不可执行——总市值约 404 万美元、20 日均成交额约 43.6 万美元、盘前仅 22 股成交、量比 0.04，任何仓位都会自我冲击价格；趋势上近 20 日 -19.4%、13 周轨迹冲高回落，做多无基本面支撑，做空又不满足强空催化红线。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事实层：SEC EDGAR 一手 6-K 载明纳斯达克于 9/3 通知 Galmed 已重新满足 Rule 5550(a)(2)，因 8/20–9/2 连续 10 个交易日收盘买价≥1 美元，退市缺陷结案；文件仅并入既有 S-8/F-3 注册声明，无新经营或财务信息。影响链：解除退市威胁对股东是轻微正向，但该「疗效」的充分条件就是股价本身已在 1 美元上方站稳 10 天，市场在 8 月中下旬已完整观测并定价，9/8 的备案不构成新增可交易事实；此后也没有被动资金流、指数资格或流通盘变化。价格与证据层：现价 3.88 美元、市值约 404 万美元、20 日均成交额约 43.6 万美元、盘前 22 股几无量、量比 0.04，近 20 日 -19.4%、距 52 周高 -70.6%，13 周轨迹 100→118→92 为冲高回落的下行形状；做多缺乏基本面支撑，做空亦不满足红线（无造假、下修、处罚等强空催化，行政合规结案反而是弱正面）。结论：无增量事实 + 无流动性 + 无 edge，AVOID；因事件方向为正面且无已确认净损害，不登记 risk_signals。
🔎 新鲜度:最早出现 2026-09-08 · 扩散 low · price-in 风险 high ↗
关键理由
- 不做多：达标事实即「股价已连续 10 日≥1 美元」，市场在 8/20–9/2 已完整观测，9/8 备案零增量，price-in 已完成
- 不做空：合规结案属弱正面行政事件，无造假/指引下修/监管处罚等强空催化，不满足做空红线；且 13 周轨迹下行只是背景而非催化
- 结构上不可执行：总市值约 404 万美元、20 日均成交额约 43.6 万美元、盘前仅 22 股成交，任何有意义仓位都会自我冲击价格
主要风险
- 极端微型股（市值约 404 万美元）叠加多个仍有效的 F-3/S-8 注册声明，未来存在继续摊薄或再次跌破 1 美元的存量风险，但这不是本事件新增的确认性净损害
- 若误把本备案当作利好追入，可能在下行趋势与极低流动性中无法按计划止损出场
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-09-08 · 影响 invalidates
未找到支持做多的增量：市值约 404 万美元、20 日均成交额约 43.6 万美元、盘前成交 22 股、量比 0.04；近 5 日 -6.84%、近 20 日 -19.42%、距 52 周高 -70.61%，path_13wk_idx100 由 100→118→92 呈冲高回落的下行形状，9/4 收盘 3.88 美元且当日高开低走（开 4.07、高 4.23、收 3.88）
检索:GLMD.US 行情与 20 日逐日走势、13 周轨迹、成交额与量比（stock_quote full） - 做空前查反向 · 来源 web · 日期 2026-09-08 · 影响 none
已处理消息库返回 0 条候选，说明这条具体催化未被其它源处理过；但这只影响新鲜度判断，不改变内容性质——备案本身无强空催化（无造假、指引下修、处罚或核心逻辑证伪），做空红线不满足
检索:Galmed 纳斯达克最低买价 重新合规 6-K 跨源查重（search_processed_events，72 小时） 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失未改变结论：AVOID 的依据是无增量事实、无流动性与无 edge，而非幅度估计
方向:未做先例定价：本次 6-K 是对已公开可观测价格事实的滞后行政确认，不含增量经济信息，任何先例统计都无法改变「不做」的结论
涨幅量级:无高相似先例可用于校准幅度；且标的日均成交额约 43.6 万美元，幅度校准对执行无意义
形态:无先例面板，不作见光死/高开低走判断；仅从本标的自身轨迹看，13 周指数化路径 100→118→92 为冲高回落，近 20 日 -19.4%，不存在与本备案同向的重定价
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 32 ms
{"result": "search_processed_events:agent query=`galmed pharmaceuticals nasdaq minimum bid price compliance | galmed 重新符合纳斯达克最低买价要求 | glmd nasdaq listing rule 5550(a)(2) regained compliance | 纳斯达克最低买价合规 退市风险解除 6-k`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 55.5/72 小时、265 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有 - stock_quote 成功 stock_tools HTTP · 683 ms
{ - fetch_decision_experience 成功 stock_tools HTTP · 11 ms
{
原文全文
展开原文 · 2,563 字
----- form6-k.htm -----
6-K
1
form6-k.htm
6-K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of September 2026
001-36345
(Commission
File Number)
GALMED
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
c/o
Meitar Law Offices Abba Hillel Silver Rd.,
Ramat
Gan, 5250608
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
On
September 3, 2026, the Nasdaq Listing Qualifications Staff notified Galmed Pharmaceuticals Ltd. (the “Company”) that it had
regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company is now in compliance
with all applicable listing standards, and its ordinary shares will continue to be listed and traded on The Nasdaq Stock Market.
The
Company was previously notified by Nasdaq on January 29, 2026 that it had failed to maintain a minimum bid price of $1.00 per share for
30 consecutive trading days, as required by Nasdaq Listing Rule 5550(a)(2), and was provided until July 28, 2026 to regain compliance.
The Company did not regain compliance during the initial 180-calendar-day compliance period and subsequently received an additional 180-calendar-day
compliance period to cure the deficiency.
To
regain compliance with the minimum bid price requirement, the Company was required to maintain a closing bid price of at least $1.00
per share for a minimum of 10 consecutive trading days. From August 20, 2026 through September 2, 2026, the closing bid price of the
Company’s ordinary shares was $1.00 per share or greater for 10 consecutive trading days. As a result, the Company has regained
compliance with Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.
This
Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos.
333-206292
,
333-227441
,
333-284163
and
333-290399
) and the Company’s Registration Statement on Form F-3 (Registration Nos.
333-272722
and
333-283241
).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Galmed
Pharmaceuticals Ltd.
Date:
September 8, 2026
By:
/s/
Allen Baharaff
Allen
Baharaff
President
and Chief Executive Officer
6-K
1
form6-k.htm
6-K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of September 2026
001-36345
(Commission
File Number)
GALMED
PHARMACEUTICALS LTD.
(Exact
name of Registrant as specified in its charter)
c/o
Meitar Law Offices Abba Hillel Silver Rd.,
Ramat
Gan, 5250608
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
On
September 3, 2026, the Nasdaq Listing Qualifications Staff notified Galmed Pharmaceuticals Ltd. (the “Company”) that it had
regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company is now in compliance
with all applicable listing standards, and its ordinary shares will continue to be listed and traded on The Nasdaq Stock Market.
The
Company was previously notified by Nasdaq on January 29, 2026 that it had failed to maintain a minimum bid price of $1.00 per share for
30 consecutive trading days, as required by Nasdaq Listing Rule 5550(a)(2), and was provided until July 28, 2026 to regain compliance.
The Company did not regain compliance during the initial 180-calendar-day compliance period and subsequently received an additional 180-calendar-day
compliance period to cure the deficiency.
To
regain compliance with the minimum bid price requirement, the Company was required to maintain a closing bid price of at least $1.00
per share for a minimum of 10 consecutive trading days. From August 20, 2026 through September 2, 2026, the closing bid price of the
Company’s ordinary shares was $1.00 per share or greater for 10 consecutive trading days. As a result, the Company has regained
compliance with Nasdaq Listing Rule 5550(a)(2), and the matter is now closed.
This
Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos.
333-206292
,
333-227441
,
333-284163
and
333-290399
) and the Company’s Registration Statement on Form F-3 (Registration Nos.
333-272722
and
333-283241
).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Galmed
Pharmaceuticals Ltd.
Date:
September 8, 2026
By:
/s/
Allen Baharaff
Allen
Baharaff
President
and Chief Executive Officer
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。